MDT

87.42

+0.36%↑

A

116.75

+1.44%↑

VEEV

158.45

+4.62%↑

HQY

79.65

+1.96%↑

TLRY

6.66

+1.22%↑

MDT

87.42

+0.36%↑

A

116.75

+1.44%↑

VEEV

158.45

+4.62%↑

HQY

79.65

+1.96%↑

TLRY

6.66

+1.22%↑

MDT

87.42

+0.36%↑

A

116.75

+1.44%↑

VEEV

158.45

+4.62%↑

HQY

79.65

+1.96%↑

TLRY

6.66

+1.22%↑

MDT

87.42

+0.36%↑

A

116.75

+1.44%↑

VEEV

158.45

+4.62%↑

HQY

79.65

+1.96%↑

TLRY

6.66

+1.22%↑

MDT

87.42

+0.36%↑

A

116.75

+1.44%↑

VEEV

158.45

+4.62%↑

HQY

79.65

+1.96%↑

TLRY

6.66

+1.22%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Open

SectorHealthcare

3.06

Overview

Share price change

24h

Current

Min

3.02

Max

3.1

Key metrics

By Trading Economics

Income

-15M

-40M

Sales

8.2M

50M

Profit margin

-80.43

Employees

435

EBITDA

-19M

-42M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+30.29% upside

Dividends

By Dow Jones

Next Earnings

11 maj 2026

Market Stats

By TradingEconomics

Market Cap

-36M

1.1B

Previous open

3.06

Previous close

3.06

News Sentiment

By Acuity

50%

50%

148 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 kwi 2026, 23:44 UTC

Market Talk
Major News Events

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12 kwi 2026, 23:38 UTC

Market Talk
Major News Events

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12 kwi 2026, 23:38 UTC

Market Talk

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12 kwi 2026, 23:36 UTC

Market Talk
Major News Events

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12 kwi 2026, 23:31 UTC

Market Talk

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12 kwi 2026, 23:09 UTC

Market Talk
Major News Events

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12 kwi 2026, 23:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 kwi 2026, 23:06 UTC

Market Talk

Australian Dollar Ripe for a Downward Correction -- Market Talk

12 kwi 2026, 22:56 UTC

Major News Events

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12 kwi 2026, 22:54 UTC

Major News Events

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12 kwi 2026, 22:53 UTC

Major News Events

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12 kwi 2026, 22:51 UTC

Major News Events

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12 kwi 2026, 22:50 UTC

Market Talk
Major News Events

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12 kwi 2026, 22:37 UTC

Market Talk
Major News Events

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11 kwi 2026, 08:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

11 kwi 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

11 kwi 2026, 08:20 UTC

Market Talk
Major News Events

Basic Materials Roundup: Market Talk

11 kwi 2026, 00:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

Big Yachts, Big Bucks -- Barrons.com

10 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 kwi 2026, 21:01 UTC

Earnings

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk
Major News Events

Basic Materials Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 kwi 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 kwi 2026, 20:10 UTC

Acquisitions, Mergers, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 kwi 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10 kwi 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 kwi 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

30.29% upside

12 Months Forecast

Average 4 USD  30.29%

High 5 USD

Low 3 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

148 / 348 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat